Vishal and RichReady to explore the frontiers of cancer therapeutics? Discover how AUM Biosciences, with a key presence in Montgomery County, Maryland, in the BioHealth Capital Region, is revolutionizing the development of innovative oncology medicines and transforming the fight against cancer resistance. Join us on this episode of BioTalk with Rich Bendis as we chat with Vishal Doshi, Chairman & CEO of AUM Biosciences, a visionary leader in the biotech industry. Tune in to the conversation that's sparking new hope in the battle against cancer.

Listen now via your favorite podcast platforms: Apple - Google - Spotify - Amazon Music - TuneIn - YouTube -

Vishal Doshi is a distinguished leader in the biopharmaceutical industry, serving as the Chairman and Chief Executive Officer of AUM Biosciences, a company he founded with a mission to transform cancer treatment through innovative drug development. As Chairman of AUM’s Board of Directors, Vishal brings extensive experience in structuring and managing global deals, having been involved in drug development ventures worth over US$4 billion with major pharmaceutical and biotech companies.

Before founding AUM Biosciences, Vishal held senior business development and management roles at prominent global enterprises, including IQVIA, EPS International, and ICON. His strategic leadership and deal-making prowess were demonstrated when he achieved a US$145 million private equity deal with a major pharmaceutical company, resulting in the successful achievement of proof-of-concept (POC) for three major oncology drugs. These drugs are currently on the market and have achieved peak sales of over US$4 billion combined, a feat accomplished in collaboration with other founders.

Vishal’s dynamic leadership has been evident in AUM Biosciences’ rapid progress. Within just 12 months of the company’s inception, Vishal led the transition from a pre-clinical to a clinical-stage company and spearheaded the development of a portfolio of transformative cancer medicines, positioning AUM Biosciences at the forefront of oncology therapeutics.

Vishal’s accomplishments have garnered industry-wide recognition, including being awarded the 2019 Asia-Pacific Biotech Entrepreneurial Company of The Year by Frost and Sullivan. He was also nominated as a Young Global Leader by the World Economic Forum for the Class of 2021 and serves as a Key Opinion Leader to the Korean Health Industry Development Institute.

Vishal holds a Master’s Degree in Pharmaceutical Sciences from Kingston University, where his research focused on Aromatase inhibitors in Breast cancer. He also earned a Bachelor of Pharmacy degree from the University of Mumbai. With his strong academic background and unwavering commitment to innovation, Vishal Doshi continues to drive advancements in the field of oncology and remains dedicated to improving the lives of patients worldwide.